Invention Grant
- Patent Title: Combined F2-isoprostane and myleoperoxidase detection, a risk indicator for cardiovascular disease
-
Application No.: US14591381Application Date: 2015-01-07
-
Publication No.: US09612242B2Publication Date: 2017-04-04
- Inventor: Stanley L. Hazen , Renliang Zhang
- Applicant: THE CLEVELAND CLINIC FOUNDATION
- Applicant Address: US OH Cleveland
- Assignee: The Cleveland Clinic Foundation
- Current Assignee: The Cleveland Clinic Foundation
- Current Assignee Address: US OH Cleveland
- Agency: Tarolli, Sundheim, Covell & Tummino LLP
- Main IPC: G01N33/573
- IPC: G01N33/573 ; C12Q1/28 ; G01N37/00 ; G06F19/00 ; G06Q50/22 ; C12N1/28 ; A61K31/616

Abstract:
Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.
Public/Granted literature
- US20150185217A1 MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE Public/Granted day:2015-07-02
Information query
IPC分类: